Clinical Trials
25 trialsNCT03303495 2026-06-05
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Phase 3 Recruiting
NCT06750094 2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05253651 2026-06-04
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT07222800 2026-06-04
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT02997228 2026-06-03
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06696768 2026-06-03
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07527832 2026-06-03
An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.
Pfizer
Completed
NCT04449874 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT06820463 2026-06-02
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT07621497 2026-06-02
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05863195 2026-06-01
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06607458 2026-06-01
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
NCT07284849 2026-06-01
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT07500298 2026-06-01
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06614192 2026-05-28
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Active not recruiting
NCT07221357 2026-05-28
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT04929223 2026-05-26
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT02350530 2026-05-22
FORBES
Sun Yat-sen University
Phase 2 Completed
NCT04230187 2026-05-22
TRIBE-C
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05464030 2026-05-22
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
Phase 1 Recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT07359456 2026-05-19
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT06948448 2026-05-18
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting